Hims & Hers Health (HIMS) Other Non-Current Assets (2020 - 2026)
Hims & Hers Health (HIMS) reported Other Non-Current Assets of $47.6 million for Q1 2026, up 2352.37% on a YoY basis from $1.9 million in Q1 2025, and up 60.46% sequentially from $29.7 million in Q4 2025.
Hims & Hers Health (HIMS) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Hims & Hers Health (HIMS) has 7 years of Other Non-Current Assets data on file, last reported at $47.6 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 2352.37% year-over-year to $47.6 million; the trailing twelve-month figure through Mar 2026 stood at $47.6 million (up 2352.37% YoY), and the FY2025 full-year result was $29.7 million, up 3367.29% from the prior year.
- Other Non-Current Assets grew to $47.6 million in Q1 2026, from $29.7 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $47.6 million in Q1 2026 to a low of $856000.0 in Q1 2022.
- A 5-year average of $5.6 million and a median of $856000.0 in 2022 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets changed 0.0% in 2022 and soared 3367.29% in 2025, its largest moves.
- Tracing HIMS's Other Non-Current Assets over 5 years: stood at $856000.0 in 2022, then changed by 0.0% to $856000.0 in 2023, then changed by 0.0% to $856000.0 in 2024, then soared by 3367.29% to $29.7 million in 2025, then jumped by 60.46% to $47.6 million in 2026.
- Business Quant data shows HIMS's Other Non-Current Assets at $47.6 million in Q1 2026, $29.7 million in Q4 2025, and $3.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 377.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 233.20 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 169,000.00 |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn | 47.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.63 Mn |
| Dec 31, 2025 | 29.68 Mn |
| Sep 30, 2025 | 3.88 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Mar 31, 2025 | 1.94 Mn |
| Dec 31, 2024 | 856,000.00 |
| Sep 30, 2024 | 856,000.00 |
| Jun 30, 2024 | 856,000.00 |
| Mar 31, 2024 | 856,000.00 |
| Dec 31, 2023 | 856,000.00 |
| Sep 30, 2023 | 856,000.00 |
| Jun 30, 2023 | 856,000.00 |
| Mar 31, 2023 | 856,000.00 |
| Dec 31, 2022 | 856,000.00 |
| Sep 30, 2022 | 856,000.00 |
| Jun 30, 2022 | 856,000.00 |
| Mar 31, 2022 | 856,000.00 |
| Dec 31, 2021 | 856,000.00 |
| Sep 30, 2021 | 856,000.00 |
| Jun 30, 2021 | 856,000.00 |